Group items tagged

This Funding Opportunity Announcement (FOA) invites applications for P30 Alzheimer's Disease Research Centers. NIA-designated Alzheimer's Disease Research Centers (ADRCs) serve as major sources of discovery into the nature of Alzheimers disease (AD) and related dementias and into the development of more effective approaches to prevention, diagnosis, care, and therapy. They contribute significantly to the development of shared resources that support dementia-relevant research, and they collaborate and coordinate their research efforts with other NIH-funded programs and investigators.

With a rapidly growing aged U.S. population, maintenance of cognitive function has become increasingly critical for the health, welfare, and well-being of the country's citizens. According to a recent survey conducted by the AARP, virtually all adults age 40+ believe maintaining or improving brain health is important; three-quarters of adults age 40+ are concerned about their brain health declining in the future.  Although chronological age itself remains the strongest predictor of age-related cognitive decline and many forms of dementia, including Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD), it has become clear that there are protective factors against these outcomes that are poorly understood. These factors have often been described as imparting resilience or resistance to age-related changes in brain structure or neuropathology, building cognitive and/or brain reserve that would oppose such age-related changes or frank pathology, or augmenting other types of cognitive and brain function that would be beneficial. Some of these protective factors might suggest important intervention strategies.

Multimorbidity, having two or more chronic conditions, is a complex challenge for doctors. This challenge becomes even more complex when treating patients with Alzheimer's disease and related dementia (ADRD), as the clinical presentation and prolonged course of ADRD influence the diagnosis and treatment of comorbid illness. Compared to patients with other long-term disorders, those with dementia may have extreme multimorbidity, averaging four additional chronic medical disorders. The most common chronic comorbid conditions for ADRD patients are hypertension and diabetes, but other significant comorbidities include, but are not limited to, heart disease, heart failure, obstructive lung disease, and incontinence, as well as acute conditions like infectious diseases and hip fracture.

The ADDF seeks to support comparative effectiveness research, prevention clinical trials, and epidemiological studies that probe whether the use or choice of drugs alters the risk for dementia or cognitive decline. Specifically, the Prevention Beyond the Pipeline RFP supports: * Studies Leveraging the Consortium of Cohorts for Alzheimer's Prevention Action (CAPA) * Comparative Effectiveness Research: Methods may include randomized trials or epidemiology. * Studies of Cognitive Decline and Cognitive Reserve: Methods may include epidemiology or clinical trials. Current target areas of interest include: - Epigenetics - Inflammation - Mitochondria & metabolic function - Neuroprotection - Proteostasis - Synaptic activity and neurotransmitters - Vascular function - Other aging targets (e.g. senescent cells) - Other novel targets or pathways that are supported by compelling evidence demonstrating a rational biological connection to age-related cognitive decline or dementia risk   

This Funding Opportunity Announcement (FOA) invites applications that focus on clarifying the relationship between delirium and Alzheimer's disease and related dementias (ADRD). Specifically sought is research focusing on understanding why persons with ADRD are at increased risk to develop delirium, often with a worse prognosis compared to those without antecedent ADRD, and why patients who experience delirium are at higher risk to develop subsequent short- and/or long-term mild cognitive impairment or ADRD, often with an accelerated rate of cognitive decline compared to those without preceding delirium. Relevant research projects may focus on, but are not limited to, those that A) provide insight into possible common, sequential, causative, contributory and/or synergistic pathways underlying both ADRD and delirium, B) elucidate mechanisms that lead to the development of delirium against the background of aging and/or neurodegeneration, with particular emphasis on use of appropriate animal models, C) identify risk factors for the onset and/or progression of delirium in those with ADRD and vice versa, D) diagnose and assess one condition in the setting of the other, E) identify putative phenotypes of patients with co-existing ADRD and delirium, or F) test pharmacologic and/or non-pharmacologic strategies to prevent, treat, or reduce the impact of delirium in patients with ADRD and vice versa. Research supported by this FOA is intended to provide mechanistic insight to improve risk assessment, diagnosis, phenotyping, prevention, and management approaches for both delirium and ADRD.

This FOA invites applications that will combine multiple cohorts in order to improve statistical power and clarify risk and protective factors for Alzheimer's disease and related dementias (AD/ADRD).

The purpose of this FOA is to support innovative interdisciplinary, multi-institute research that will lead to the identification and validation of molecular mechanisms relevant to human biology that contribute to tau toxicity associated with Frontotemporal Degeneration (FTD). It is anticipated that this research will also contribute to tool development that can be applied to target validation in FTD clinical trials.Applications must include an administrative core, a scientific governance structure, a minimum of three research projects with milestone plans, resource core(s) that support the basic research efforts of at least two proposed research projects, a data coordination core that will facilitate the distribution of data generated through the Center without Walls with the broad research community and a human biology validation core that will support the validation of mechanisms identified and resources developed under this FOA. Synergy must be evident among Center research projects and cores, such that successful completion of the aims could not be accomplished without the Center structure. This FOA is in response to the Alzheimer's Disease Related Dementias (ADRD) challenges outlined in the 2015 update to the National Plan to Address Alzheimer's Disease.

The purpose of this FOA is to support innovative interdisciplinary, multi-institute research that will lead to the identification and validation of molecular mechanisms relevant to human biology that contribute to tau toxicity associated with Frontotemporal Degeneration (FTD). It is anticipated that this research will also contribute to tool development that can be applied to target validation in FTD clinical trials.Applications must include an administrative core, a scientific governance structure, a minimum of three research projects with milestone plans, resource core(s) that support the basic research efforts of at least two proposed research projects, a data coordination core that will facilitate the distribution of data generated through the Center without Walls with the broad research community and a human biology validation core that will support the validation of mechanisms identified and resources developed under this FOA. Synergy must be evident among Center research projects and cores, such that successful completion of the aims could not be accomplished without the Center structure. This FOA is in response to the Alzheimer's Disease Related Dementias (ADRD) challenges outlined in the 2015 update to the National Plan to Address Alzheimer's Disease.

This FOA invites applications that will systematically and comprehensively characterize alpha-synuclein and amyloid-beta subspecies present in human Lewy Body Dementia (LBD) post-mortem brain tissue, identify toxic subspecies and potential mechanisms of toxicity, and characterize any interactions between the proteins that may contribute to increased toxicity and/or explain selective vulnerabilities of cells/circuits. Applications are required to include at least 3 hypothesis-driven projects that address these goals, an administrative core, and other cores as appropriate. Applicants will be expected to focus on the use of human tissues. All applications will be expected to include plans for developing a publicly-available library of fully characterized alpha-synuclein and amyloid-beta subspecies found in LBD.

he goal of this Funding Opportunity Announcement (FOA) is to encourage applications for studies that will enhance knowledge of mechanisms associated with neuropsychiatric symptoms (NPS) in persons with Alzheimer's disease (AD) or Alzheimer's disease-related dementias (ADRD). The findings from such research are expected to advance mechanistic understanding of both biobehavioral and neurobiological pathways leading to NPS, and may provide insights into novel targets for interventions that might alleviate some burden associated with these symptoms, or suggest strategies for preventing the development of NPS as related to AD or ADRD 

This Funding Opportunity Announcement (FOA) invites applications to provide infrastructure support for advancing development of specific high-priority areas of behavioral and social research of relevance to Alzheimer's disease and Alzheimer's disease related dementias (AD/ADRD). The infrastructure support will facilitate research networks through meetings, conferences, small-scale pilots, short-term educational opportunities (such as intensive workshops, summer institutes, or visiting scholar programs), and dissemination to encourage growth and development of specified priority areas and build resources for advancing aging-relevant research in the field at large. Network applications are limited to the following areas: (1) AD/ADRD care and services research, and (2) the coordination of international studies conducting the Harmonized Cognitive Assessment Protocol.

This Funding Opportunity Announcement (FOA) invites applications to provide infrastructure support to provide infrastructure support for advancing development of specific high priority areas of behavioral and social research of relevance to Alzheimers disease and Alzheimers disease related dementias (AD/ADRD). The infrastructure support will facilitate research networks through meetings, conferences, small scale pilots, short term educational opportunities (such as intensive workshops, summer institutes, or visiting scholar programs), and dissemination to encourage growth and development of specified priority areas and build resources for advancing aging-relevant research in the field at large. Network applications are limited to the following areas: (1) AD/ADRD care and services research and (2) the coordination of international studies conducting the Harmonized Cognitive Assessment Protocol.

The goal of this Funding Opportunity Announcement (FOA) is to encourage applications for studies that will enhance knowledge of mechanisms associated with neuropsychiatric symptoms (NPS) in persons with Alzheimer's disease (AD) or Alzheimer's disease-related dementias (ADRD). The findings from such research are expected to advance mechanistic understanding of both biobehavioral and neurobiological pathways leading to NPS, and may provide clues to novel intervention targets for alleviating some of the burden associated with these symptoms, or suggest optimal prevention strategies.

The goal of this Funding Opportunity Announcement (FOA) is to encourage applications for studies that will enhance knowledge of mechanisms associated with neuropsychiatric symptoms (NPS) in persons with Alzheimer's disease (AD) or Alzheimer's disease-related dementias (ADRD).The findings from such research are expected to advance mechanistic understanding of both biobehavioral and neurobiological pathways leading to NPS, and may provide insights into novel targets for interventions that might alleviatesomeburden associated with these symptoms, or suggest strategies for preventing the development of NPS as related to AD or ADRD RFA-MH-19-510 uses the R01 grant mechanism, whileRFA-MH-19-511 uses the R21 mechanism. High risk/high payoff projects that lack preliminary data or utilize existing data may be most appropriate for the R21 mechanism.

This FOA invites applications that propose to develop, characterize and validate innovative human cellular model systems that recapitulate phenotypic, mechanistic and neuropathological hallmarks of  Alzheimer's Disease-Related Dementias (ADRDs). Model systems will be expected to capture the complex, multi-faceted proteinopathies and/or vascular pathology observed in ADRDs, with multiple cell types represented in each model. Years 3-5 will focus on the extensive characterization and perturbation of the cellular model systems. The overall goal of this FOA is to establish next generation human cellular model systems for ADRDs to serve as tools to interrogate molecular disease mechanisms and identify potential therapeutic targets.

The purpose of the FOA is to support the large scale molecular platform analysis of brain tissue, human biofluid or human induced pluripotent stem cell resources for the identification of targets and pathways associated with Alzheimer's Disease Related Dementias (ADRDs) pathophysiology.

The purpose of the FOA is to support the large scale molecular platform analysis of brain tissue, human biofluid or human induced pluripotent stem cell resources for the identification of targets and pathways associated with Alzheimer's Disease Related Dementias (ADRDs) pathophysiology.

This Funding Opportunity Announcement (FOA) invites applications focused on interpersonal processes in the context of triadic interactions in clinical contexts involving caregivers, individuals with Alzheimer's disease and Alzheimer's disease related dementias (AD/ADRD), and health care practitioners and the impact of those processes on patient outcomes. The goal of this initiative is to support research that can lead to the development of interventions for optimizing communication among patients, caregivers, and healthcare practitioners and for preserving strong and supportive caregiving relationships throughout disease progression along the continuum of care for people with AD/ADRD. To these ends, basic research and translational research is solicited in two high-priority areas: (1) effective communications and relationships among patients, healthcare practitioners, and caregivers; and (2) associations between close relationship processes and health in caregiving relationships.

This Small Research Grant Program supports important and innovative research in areas in which more scientific investigation is needed to improve the prevention, diagnosis, treatment and care for Alzheimer's disease and related dementias (AD/ADRD). The program seeks (i) to facilitate the next generation of researchers in the United States to pursue research and academic careers in neurosciences, AD/ADRD and healthy brain aging, and (ii) to stimulate established researchers who are not currently doing AD/ADRD research to perform pilot studies toward developing new innovative AD/ADRD research programs that leverage and build upon their existing expertise. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.

To study in vivo synaptic structure and function in Alzheimer's and related dementia; and to advance development of methods to study synapses in animal models and humans.

This Small Research Grant Program supports important and innovative research in areas in which more scientific investigation is needed to improve the prevention, diagnosis, treatment and care for Alzheimer's disease and related dementias. The program seeks to stimulate the next generation of researchers in the United States to pursue research and academic careers in neurosciences, Alzheimer's disease and healthy brain aging.